Financials
Financial year 2024
Worth noting
- The team shrank two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ 1.4 million
▼ 18% vs 2023
Profit
Growing€ 156,990
▲ 140% vs 2023
Debts
High€ 4.3 million
▲ 47% vs 2023
BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL from Gent, company number BE0475471036, closed financial year 2024 with a result of € 156,990 after tax. For that financial year BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL recorded a gross margin of € 1.4 million and equity of € 586,742. Compared with financial year 2023, the result moved from € 65,528 to € 156,990. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2025.
What happened at BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL?
What happened at BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 156,990 (▲ 140% vs 2023). filed late Source: NBB ↗
- A.I.P. NV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 209,789 loss in 2021 to € 156,990 profit in 2024.
Paid € 1,216 in corporate taxes since 2021.
Best year ever: 2022, with € 291,274 profit.
On average € 95,600 of value added per employee in 2024.
A new publication or filing at BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL? We notify you, reason included.
Follow BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROLNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL is A.I.P. NV.
Directors
According to the 2024 annual accounts
Director · represented by Hugo VAN HEUVERSWYN
since 2020
Establishments
Establishment units
Physical locations of this company
Rijvisschestraat 118 box 1
9052 Gent
Klaartestraat 16
9052 Gent
Active since 11 September 2001
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
Advanced incubation platform same network
€ 867,263 gross margin · 2024
STAPLES BELGIUM
€ 676,401 gross margin · 2025
GROUP AIP
INTEGRA CAPITAL PARTNERS
€ 327,777 gross margin · 2024
INTEGRA FUND PRIVAK
+16 more
Details
- Company number
- 0475.471.036
- VAT number
- BE 0475.471.036
- Registered office
- Rijvisschestraat 118 bus 1, 9052 Gent
- Names & denominations
- BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL · BIOMARIC
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 August 2001
- Peppol
- Active · Active since 31 Oct 2023
- Activities · NACE
Medische laboratoria
Activiteiten van medische beeldvorming en medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied